Cassava Sciences Licenses Simufilam Method of Treatment Patent

Stock Information for OptiNose Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OptiNose Inc.

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAVA
SAVA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action - SAVA
Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.